Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | BACIGUENT | — | 1948-09-08 | fda.gov ↗ |
Trials 16
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05449392 | Sep 2022 → Sep 2023 | COVID-19 | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT00479193 | Oct 2006 → Dec 2008 | — | MetroHealth Medical Center | Withdrawn | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01222832 | Jul 2010 → Jun 2012 | paranasal sinus disorder | Steward St. Elizabeth's Medical Center of Boston, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00132600 | Apr → Jul 2005 | allergic contact dermatitis | Mekos Laboratories AS | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05874219 | Apr → May 2023 | — | Future University in Egypt | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT01002911 | Dec 2009 → Jan 2012 | cardiac rhythm disease | Population Health Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT00640614 | Apr 2008 → Aug 2009 | contact dermatitis | Allerderm | Completed | No outcome recorded |
| Phase 44 trials · 1 met primary · 1 missed | ||||||
| Phase 4 | NCT03199911 | Oct 2017 → Nov 2019 | drug allergy, eyelid disorder, poisoning, skin cancer | University of California, San Francisco | Completed | Met primary |
| Phase 4 | NCT01628666 | Dec 2012 → Sep 2017 | cardiac rhythm disease | Population Health Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT01668030 | Feb 2012 → Nov 2013 | — | University of Louisville | Completed | Missed primary |
| Phase 4 | NCT00671541 | Mar 2006 → Feb 2012 | chronic rhinosinusitis | Lahey Clinic | Withdrawn | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT07549828 | Apr 2026 → Mar 2029 expected | acne, atopic eczema, psoriasis, seborrheic dermatitis | National Taiwan University Hospital | Not yet recruiting | No outcome recorded |
| — | NCT04438655 | May 2019 → Nov 2021 | — | University of Turin, Italy | Completed | No outcome recorded |
| — | NCT00990392 | Nov 2009 → Jan 2011 | bacterial infectious disease with sepsis, skin infection | Fraser Health | Withdrawn | No outcome recorded |
| — | NCT00997139 | Sep 2009 → Nov 2010 | — | Northwestern University | Completed | No outcome recorded |
| — | NCT00705354 | Jan 2009 → Oct 2010 | chronic rhinosinusitis | Lahey Clinic | Withdrawn | No outcome recorded |
| Comparator or background therapy16 trials | ||||||
| Phase 0 | NCT02099240 Comparator | Mar 2014 → Nov 2018 | osteomyelitis | University of Louisville | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03213249 Comparator | Jul 2017 → Sep 2018 | breast disorder | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT01359735 Comparator | May → Nov 2011 | skin cancer | Healthpoint | Completed | No outcome recorded |
| Phase 2/3 | NCT00674999 Comparator | Jun 2005 → Sep 2008 | — | The University of Texas Medical Branch, Galveston | Withdrawn | No outcome recorded |
| Phase 3 | NCT02809131 Comparator | Apr 2016 → Mar 2021 | sick sinus syndrome, systolic heart failure, third-degree atrioventricular block | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT03929224 Comparator | Oct 2018 → Sep 2020 | skin infection | Henry Ford Health System | Completed | No outcome recorded |
| Phase 4 | NCT02106962 Background | Apr → Aug 2014 | arteriovenous hemangioma/malformation | California Institute of Renal Research | Completed | No outcome recorded |
| Phase 4 | NCT02673229 Comparator | Sep 2013 → Dec 2018 | — | University of Kansas Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01516463 Comparator | Mar 2012 → Jun 2013 | — | Healthpoint | Withdrawn | No outcome recorded |
| Phase 4 | NCT01350102 Comparator | Feb 2012 → Mar 2014 | type 1 diabetes mellitus, type 2 diabetes mellitus, ulcer of lower limbs | Susan Hassenbein | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01613092 Comparator | May 2011 → Nov 2013 | cardiac rhythm disease | Population Health Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT00634166 Background | Sep 2007 → Dec 2013 | — | Mylan Inc. | Terminated | No outcome recorded |
| — | NCT07801157 Background | Jul 2024 → Dec 2025 | — | Mansoura University | Completed | No outcome recorded |
| — | NCT04906408 Comparator | Sep 2021 → May 2028 expected | abdominal wall malformation | Ohio State University | Recruiting | No outcome recorded |
| — | NCT02395614 Comparator | Dec 2015 → Dec 2020 | breast cancer | Vanderbilt University Medical Center | Completed | No outcome recorded |
| — | NCT02318056 Comparator | Dec 2015 → Jul 2016 | — | Southern Illinois University | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 32 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bacitracin | “'Topical Antimicrobial/Antifungal Medications' Various topical antimicrobials and antifungals include: Bacitracin; Amphotericin B; Silver Sulfadiazine; Cefazolin; Vancomycin;...” NCT00634166 ↗31“Extraoral Bacitracin-Neomycin ointment and 10% povidone-iodine, together with intraoral benzydamine hydrochloride oral spray and chlorhexidine gluconate mouthwash, administered...” NCT07801157 ↗ “Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Gold Sodium Thiosulfate, Hydrocortisone-17-Butyrate, Methyldibromoglutaronitrile, Bacitracin, Parthenolide, Disperse...” NCT00640614 ↗ “There is also the traditional wound dressing which consists of Bacitracin antibiotics on a xeroform gauze, covered with a standard abdominal pad and tape.” NCT04906408 ↗ “Single dose of Cefazolin and Vancomycin preoperatively, bacitracin wash and cefalexin post operative.” NCT01628666 ↗ “Neosporin is neomycin, bacitracin and polymyxin B with formulation 3.5mg/400 units/5,000 units.” NCT05449392 ↗ “Cefazolin and Vancomycin pre-op, bacitracin wash and postoperative cefalexin or clindamycin” NCT01613092 ↗ “triple antibiotic solution will contain 1 g of cefazolin, 50,000 U of bacitracin” NCT02395614 ↗ “Topical antibiotic ointment will be erythromycin or bacitracin.” NCT03199911 ↗ “Polysporin Triple Therapy (gramicidin, polymixin, bacitracin)” NCT00990392 ↗ “Xeroform® burn dressing and Bacitracin® topical antibiotic” NCT02318056 ↗ |
| Known as | Bacitracin zinc | “Local antibiotic spray Neomycin sulphate 165,000 IU + Bacitracin zinc 12,500 IU” NCT05874219 ↗ |
| Route | Intranasal | “placed in middle meatus of the nose” NCT00705354 ↗ |